The ABBV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABBV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABBV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABBV Detailed Price Forecast - CNN Money||View ABBV Detailed Summary - Google Finance|
|View ABBV Detailed Summary - Yahoo! Finance||View ABBV Stock Research & Analysis - Zacks.com|
|View ABBV Trends & Analysis - Trade-Ideas||View ABBV Major Holders - Barrons|
|View ABBV Call Transcripts - NASDAQ||View ABBV Breaking News & Analysis - Seeking Alpha|
|View ABBV Annual Report - CompanySpotlight.com||View ABBV OTC Short Report - OTCShortReport.com|
|View ABBV Fundamentals - TradeKing||View ABBV SEC Filings - Bar Chart|
|View Historical Prices for ABBV - The WSJ||View Performance/Total Return for ABBV - Morningstar|
|View the Analyst Estimates for ABBV - MarketWatch||View the Earnings History for ABBV - CNBC|
|View the ABBV Earnings - StockMarketWatch||View ABBV Buy or Sell Recommendations - MacroAxis|
|View the ABBV Bullish Patterns - American Bulls||View ABBV Short Pain Metrics - ShortPainBot.com|
|View ABBV Stock Mentions - StockTwits||View ABBV Stock Mentions - PennyStockTweets|
|View ABBV Stock Mentions - Twitter||View ABBV Investment Forum News - Investor Hub|
|View ABBV Stock Mentions - Yahoo! Message Board||View ABBV Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABBV - SECform4.com||View Insider Transactions for ABBV - Insider Cow|
|View ABBV Major Holdings Summary - CNBC||View Insider Disclosure for ABBV - OTC Markets|
|View Insider Transactions for ABBV - Yahoo! Finance||View Institutional Holdings for ABBV - NASDAQ|
|View ABBV Stock Insight & Charts - FinViz.com||View ABBV Investment Charts - StockCharts.com|
|View ABBV Stock Overview & Charts - BarChart||View ABBV User Generated Charts - Trading View|
AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.
Posted on Friday February 15, 2019
Announcement: Moody's announces completion of a periodic review of ratings of AbbVie Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
[$$] WSJ Tax Guide 2019: The Drug Industry
Posted on Friday February 15, 2019
The tax overhaul has given pharmaceutical companies that generate hefty sales outside the U.S. the chance to bring cash home at a preferential rate. Multinational drug companies were big beneficiaries from the tax overhaul because they generate a good chunk of their sales outside the U.S. and had been keeping billions of dollars overseas to avoid having to pay U.S. taxes on the sums. With taxes falling, drug-company profits have soared, according to a Wall Street Journal review of securities filings for the first nine months of 2018.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
Posted on Wednesday February 13, 2019
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
Posted on Tuesday February 12, 2019
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.